CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
Published on August 3, 2023
BENITEC BIOPHARMA INC.
3940 Trust Way
Hayward, California 94545
August 3, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549-1004
Attention: Jason Drory
| Re: | Benitec Biopharma Inc. |
Registration Statement on Form S-1, as amended
File No. 333-273177
Dear Mr. Drory:
Pursuant to Rule 461 of the Securities Act of 1933, as amended, Benitec Biopharma Inc. hereby requests acceleration of the effective date of the above-referenced Registration Statement on Form S-1 (File No. 333-273177), as amended, so that it may become effective at 4:30 p.m., Eastern Time on Monday, August 7, 2023, or as soon thereafter as practicable.
| Very truly yours, | ||
| BENITEC BIOPHARMA INC. | ||
| By: | /s/ Dr. Jerel Banks | |
| Name: Dr. Jerel Banks |
||
| Title: Chief Executive Officer |
||